Novel Application of Umbilical Cord Flowable Tissue Allografts in Sacral Decubitus Ulcers: A Case Study

Each year, thousands of patients suffer from sacral decubitus ulcers, also known as pressure ulcers or sores. The current standard care for ulcer treatment is expensive and suboptimal, ranging in cost a 15-dollar tube Neosporin Ointment to 240,000 dollars skin flap surgery. Grade II sores inevitably progress stage III IV if not addressed aggressively early. Late-stage present unique challenge physicians, particularly when they are deep, tunneling, have tendon bone involvement, the case two this study. first patient study (referred 1) was afflicted with mid-sacral sore exposed tendon, bone, tunneling ten years duration. second 2) suffered an ischial 30 months Both exhausted conservative measures, including wound vac placement, oral antibiotic treatment, multiple episodes sharp debridement, wet-to-dry dressings, silver sulfadiazine dehydrated amniotic membrane allograft placements. After failing management, both received several applications Wharton’s Jelly, Mesenchymal Connective Tissue (MCT), accelerate closure. Conservative antibiotics, electrical stimulation, used conjunction WJ applications. At time consultation Dr. Michael Lavor, had Sacral Decubitus Ulcers (SDU) classified Stage tissue loss involvement according National Pressure Ulcer Advisory Panel (NPUAP). eight standardized combined six Jelly applications, wounds showing over 90% contraction depth, diameter. This demonstrates precedent applying allografts late-stage associated combination care. Future research efforts applied recalcitrant may be directed at frequency procedural techniques that best promote granulation formation volumetric contracture deep by secondary intention.